References
Activated Charcoal
15
McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
126
Kaaja RJ, Kontula KK, Raiha A, Laatikainen T. Treatment of cholestasis of pregnancy with peroral activated charcoal. A preliminary study. Scand J Gastroenterol 1994;29:178-81. View abstract.
12392
Anon. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999;37:731-51. View abstract.
12393
Bond GR. The role of activated charcoal and gastric emptying in gastrointestinal decontamination: a state-of-the-art review. Ann Emerg Med 2002;39:273-86. View abstract.
12394
Anon. Position paper: Ipecac syrup. J Toxicol Clin Toxicol 2004;42:133-43. View abstract.
12395
Hall RG Jr, Thompson H, Strother A. Effects of orally administered activated charcoal on intestinal gas. Am J Gastroenterol 1981;75:192-6. View abstract.
12396
Suarez FL, Furne J, Springfield J, Levitt MD. Failure of activated charcoal to reduce the release of gases produced by the colonic flora. Am J Gastroenterol 1999;94:208-12. View abstract.
12397
Neuvonen PJ, Kuusisto P, Vapaatalo H, Manninen V. Activated charcoal in the treatment of hypercholesterolaemia: dose-response relationships and comparison with cholestyramine. Eur J Clin Pharmacol 1989;37:225-30. View abstract.
12398
Park GD, Spector R, Kitt TM. Superactivated charcoal versus cholestyramine for cholesterol lowering: a randomized cross-over trial. J Clin Pharmacol 1988;28:416-9. View abstract.
12399
Hoekstra JB, Erkelens DW. No effect of activated charcoal on hyperlipidaemia. A double-blind prospective trial. Neth J Med 1988;33:209-16.
12400
Hoegberg LC, Angelo HR, Christophersen AB, Christensen HR. Effect of ethanol and pH on the adsorption of acetaminophen (paracetamol) to high surface activated charcoal, in vitro studies. J Toxicol Clin Toxicol 2002;40:59-67. View abstract.
93198
Brahmi N, Kouraichi N, Thabet H, Amamou M. Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. Am J Emerg Med 2006;24(4):440-3. View abstract.
93199
Coffin B, Bortolloti C, Bourgeouis O, Denicourt L. Efficacy of a simethicone, activated charcoal and magnesium oxide combination (Carbosymag) in functional dyspepsia: results of a general practice-based randomized trial. Clin Res Hepatol Gastroenterol 2011;35(6-7):494-9. View abstract.
93200
Cooper GM, Le Couteur DG, Richardson D, Buckley NA. A randomized clinical trial of activated charcoal for the routine management of oral drug overdose. QJM 2005;98(9):655-60. View abstract.
93601
Eddleston M, Juszczak E, Buckley NA, et al. Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet 2008;371(9612):579-87. View abstract.
93602
Gude AB, Hoegberg LC, Angelo HR, Christensen HR. Dose-dependent adsorptive capacity of activated charcoal for gastrointestinal decontamination of a simulated paracetamol overdose in human volunteers. Basic Clin Pharmacol Toxicol 2010;106(5)406-10. View abstract.
93603
Kerihuel JC. Effect of activated charcoal dressings on healing outcomes of chronic wounds. J Wound Care. 2010;19(5):208,210-2,214-5. View abstract.
93604
Lecuyer M, Cousin T, Monnot MN, Coffin B. Efficacy of an activated charcoal-simethicone combination in dyspeptic syndrome: results of a randomized prospective study in general practice. Gastroenterol Clin Biol 2009;33(6-7):478-84. View abstract.
93606
Mullins M, Froelke BR, Rivera MR. Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. Clin Toxicol (Phila) 2009;47(2):112-5. View abstract.
93607
Roberts DM, Southcott E, Potter JM, et al. Pharmacokinetics of digoxin cross-reacting substances in patients with acute yellow oleander (Thevetia peruviana) poisoning, including the effect of activated charcoal. Ther Drug Monit 2006;28(6):784-92. View abstract.
93608
Sergio GC, Felix GM, Luis JV. Activated charcoal to prevent irinotecan-induced diarrhea in children. Pediatr Blood Cancer 2008;51(1):49-52. View abstract.
93609
Skinner CG, Chang AS, Matthews AS, Reedy SJ, Morgan BW. Randomized controlled study on the use of multiple-dose activated charcoal in patients with supratherapeutic phenytoin levels. Clin Toxicol (Phila) 2012;50(8):764-9. View abstract.
93610
Wananukul W, Klaikleun S, Sriapha C, Tongpoo A. Effect of activated charcoal in reducing paracetamol absorption at supra-therapeutic dose. J Med Assoc Thai 2010;93(10):1145-9. View abstract.
93611
Wang Z, Cui M, Tang L, et al. Oral activated charcoal suppresses hyperphosphataemia in haemodialysis patients. Nephrology (Carlton) 2012;17(7):616-20. View abstract.
93612
Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014;14(2):147-54. View abstract.
93613
Chyka PA, Seger D, Krenzelok EP, et al. Position paper: single-dose activated charcoal. Clin Toxicol (Phila) 2005;43(2):61-87. View abstract.
93614
Kerihuel JC. Charcoal combined with silver for the treatment of chronic wounds. Wounds UK 2009;5(3):87-93.
94730
Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2018;2:CD003328. View abstract.
94731
Mulligan CM, Bragg AJ, O'Toole OB. A controlled comparative trial of Actisorb activated charcoal cloth dressings in the community. Br J Clin Pract 1986;40(4):145-8. View abstract.
103192
Elomaa K, Ranta S, Tuominen J, Lähteenmäki P. Charcoal treatment and risk of escape ovulation in oral contraceptive users. Hum Reprod. 2001;16(1):76-81. View abstract.
103193
Gao Y, Wang G, Li Y, Lv C, Wang Z. Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease. J Nephrol. 2019;32(2):265-72. View abstract.
105543
Skov K, Graudal NA, Jürgens G. The effect of activated charcoal on drug exposure following intravenous administration: A meta-analysis. Basic Clin Pharmacol Toxicol 2021;128(4):568-578. View abstract.
105816
Gao Y, Shao J, Jiang Z, et al. Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Discov Today 2014;19(3):326-40. View abstract.
105817
Ibarra M, Troconiz IF, Fagiolino P. Enteric reabsorption processes and their impact on drug pharmacokinetics. Sci Rep 2021;Mar 11;11(1):5794. View abstract.
105818
Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic, and clinical implications. Clin Pharmacokinet 2002;41(10):751-90. View abstract.
108852
Isoardi KZ, Henry C, Harris K, Isbister GK. Activated Charcoal and Bicarbonate for Aspirin Toxicity: a Retrospective Series. J Med Toxicol 2022;18(1):30-37. View abstract.
108853
Ali R, Irfan M, Akram U, et al. Efficacy of Natural Formulation Containing Activated Charcoal, Calcium Sennosides, Peppermint Oil, Fennel Oil, Rhubarb Extract, and Purified Sulfur (Nucarb®) in Relieving Constipation. Cureus 2021;13(10):e18419. View abstract.
108854
Espinoza B, Zingale D, Rubal-Peace G. Prevalence of medically unsupervised activated charcoal use a cause for concern in celiac disease?. J Am Pharm Assoc (2003) 2022;62(2):546-550. View abstract.
111718
Butera A, Pascadopoli M, Gallo S, et al. Evaluation of the Efficacy of Low-Particle-Size Toothpastes against Extrinsic Pigmentations: A Randomized Controlled Clinical Trial. Dent J (Basel) 2023;11(3):82. View abstract.